MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied in metabolic signaling and cellular stress responses. Its name refers to a mitochondrial open reading frame associated with the 12S ribosomal RNA region. It is a research topic, not a synonym for an established anti-aging treatment.

What the early studies measured

The 2015 discovery paper investigated cellular metabolism and reported effects on metabolic regulation in mice. It proposed signaling involving the AMPK pathway, which participates in cellular energy sensing. These experiments supplied mechanistic and preclinical evidence, not proof of clinical benefit. Lee and colleagues, 2015

A later paper studied both people and experimental models, but the kinds of evidence were different. Its human component examined changes in naturally occurring MOTS-c around exercise. Administration experiments examining physical performance were performed in mice. These findings should not be combined into the claim that injected MOTS-c has been shown to improve human exercise performance. Reynolds and colleagues, Nature Communications, 2021

What remains uncertain

Measuring an endogenous peptide is not the same as testing a manufactured drug. A meaningful human evaluation would need a defined formulation, reliable exposure measurements, suitable controls, clinically relevant outcomes and systematic safety follow-up. Results would also need to be reproducible and applicable to the population being discussed.

An apparent rise or fall in a peptide can be a cause, a consequence, a compensatory response, or a measurement artifact. Establishing which explanation is correct requires more than an association.

How to interpret current marketing

Descriptions such as “exercise in a vial” or “proven longevity peptide” go beyond the cited studies. They compress complex experiments into a promise those experiments did not test. The defensible educational conclusion is narrower: MOTS-c is a biologically interesting signal with preclinical findings and human physiological observations; those categories should remain clearly labeled.

U.S. regulatory context: November 4, 2026

HHS's October 30 notice describes a draft, nonbinding 503A enforcement-discretion policy that includes MOTS-c. It is conditional compounding policy, not FDA approval or a final addition to the 503A bulks list. Federal Register notice

The accompanying document specifies MOTS-c acetate and defined formulations, with conditions including a patient-specific prescription, qualified manufacturing, testing and reporting. It does not authorize arbitrary products or establish clinical effectiveness. HHS policy and appendices Recheck this evolving policy before publication. No personal-use recommendation follows.